ClinicalTrials.Veeva

Menu
V

Velocity Clinical Research | Clinical Research Institute of Southern Oregon (CRISOR)

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
BI 456906
Deudomperidone
BLU-5937
ESK-001
Albuterol Sulfate
Cadisegliatin
Survodutide
Budesonide
Rezpeg

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 17 total trials

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Active, not recruiting
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.

Active, not recruiting
Asthma
Biological: NSI-8226
Biological: Placebo

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.

Enrolling
Diabetes Mellitus, Type 1
Drug: Cadisegliatin 800 mg QD
Drug: Placebo

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Active, not recruiting
Psoriasis
Severe Psoriasis
Drug: Open-Label Envudeucitinib
Drug: Blinded Envudeucitinib

Trial sponsors

Amgen logo
C
A
A
B
Boehringer Ingelheim logo
C
Ionis Pharmaceuticals logo
Nektar Therapeutics logo
Novavax logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems